IDEXX Laboratories, Inc. vs Zoom Video Communications, Inc. — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while Zoom Video Communications, Inc. trades at $97.74 (market cap $27.62B). The key difference: IDEXX Laboratories, Inc. is the larger of the two by market cap, and Zoom Video Communications, Inc. is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and Zoom Video Communications, Inc. for 92 Days on average.
| IDXX | ZM | |
|---|---|---|
Market Cap | $40.43B | $27.62B |
Volume | 692,164 | 3,913,188 |
Sector | Health | Technology |
52-Week High | $766.68 | $111.88 |
52-Week Low | $504.70 | $72.72 |
Typical Hold Time | 46 Days | 92 Days |
Enterprise Value | $41.32B | $20.43B |
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $513.14, up 1.28% with strong fundamentals including 25.03% net income margin and 74.21% ROE. The stock shows bearish technical signals but maintains consistent earnings beats and analyst consensus of $665 price target. Recent acquisition of CoVetAI expands AI capabilities in veterinary workflow intelligence, supporting long-term growth framework.
Outlook remains positive with revenue growth accelerating to $4.3B in 2025 and projected $4.6B in 2026. Key risks include foreign exchange headwinds and weaker U.S. veterinary visits. The 56.5% buy rating from analysts suggests continued confidence in the company's diagnostic innovation pipeline and recurring revenue economics.
Zoom (ZM) trades at $94.67, down 0.11% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company reported strong profitability with a net income margin of 65.19% and ROE of 32.14% for 2025. Recent earnings beat expectations in Q1 and Q2 2026, while Q4 2025 missed. Analyst consensus price target is $118.08, implying significant upside. News highlights include AI product launches and board appointments, supporting growth initiatives.
The outlook for ZM is positive given its robust fundamentals, earnings momentum, and Wall Street's bullish stance. Key opportunities include AI-driven revenue growth and strategic investments. Risks involve competitive pressures, execution challenges, and market volatility. The stock presents a compelling case for growth investors, though careful monitoring of quarterly performance is advised.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →Zoom Video Communications, Inc. develops a people-centric cloud service that transforms real-time collaboration experience. The Company offers unified meeting experience, a cloud service that provides a 3-in-1 meeting platform with HD video conferencing, mobility, and web meetings. Zoom Video Communications serves customers worldwide.
Read more on ZM →